Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2010 | 5 | 1 | 140-143

Article title

A metastatic gastric cancer mimicking a chronic myeloproliferative disorder


Title variants

Languages of publication



It is known that coexistence of extreme thrombocytosis and thrombosis is observed frequently in chronic myeloproliferative disorders. In this paper, we report a patient who was prediagnosed with chronic myeloproliferative disorder; however, later on the diagnosis was confirmed as metastatic gastric cancer. The patient was a 75-year old female who was admitted with pain, swelling and erythema on her right arm. White blood cell count was 20 ×109/l, hemoglobin 5.2 g/dl and platelet count 1 088 ×109/l. Doppler ultrasonography revealed acute thrombotic process in right brachial vein. Since brachial vein thrombosis, thrombocytosis and anemia were seen together, the presumed diagnosis for this patient was chronic myeloproliferative disorder, and therapy with hydroxyurea, allopurinol and enoxaparin was started. One day after the heparin treatment, hematemesis and melena occurred. Eusophagogastroduodenal endoscopy showed an ulcerated and hemorrhagic polipoid lesion extending towards the cavity in the cardia region. Hydroxyurea treatment was stopped since the myeloproliferative disorder was excluded. Abdominal ultrasonography and tomography proved multiple metastatic lesions in the liver. Gastric and liver biopsies revealed “well differentiated adenocarcinoma” and 5-fluorouracil chemotherapy plus folinic acid was planned. As a result, in cases with thrombocytosis and thrombosis, metastatic cancers should be kept in mind besides chronic myeloproliferative disorders.










Physical description


1 - 2 - 2010
29 - 1 - 2010


  • Department of Internal Medicine, Ankara Numune Education and Research Hospital, 06100, Ankara, Turkey
  • Department of Hematology, Gulhane Military Medical Academy, 06018, Ankara, Turkey


  • [1] Dame C., Sutor A.H., Primary and secondary thrombocytosis in childhood, Br. J. Haematol., 2005, 129, 165–77 http://dx.doi.org/10.1111/j.1365-2141.2004.05329.x[Crossref]
  • [2] Taksin A.L., Couedic J.P., Dusanter-Fourt I., Masse A., Giraudier S., Katz A., Wendling F., et al., Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L, Blood, 1999, 93, 125–39
  • [3] Schafer A.I., Thrombocytosis, N. Engl. J. Med., 2004, 350, 1211–9 http://dx.doi.org/10.1056/NEJMra035363[Crossref]
  • [4] Coon W.W., Penner J., Clagett P., Eos N., Deep venous thrombosis and postsplenectomy thrombocytosis, Arch. Surg., 1978, 113, 429–31
  • [5] De Stefano V., Teofili L., Leone G., Michiels J.J., Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis, Semin. Thromb. Hemost., 1997, 23, 411–8 http://dx.doi.org/10.1055/s-2007-996117[Crossref]
  • [6] Lengfelder E., Hochhaus A., Kronawitter U., Höche D., Queisser W., Jahn-Eder M., et al., Should a platelet limit of 600 x 109/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages, Br. J. Haematol., 1998, 100, 15–23 http://dx.doi.org/10.1046/j.1365-2141.1998.00529.x[Crossref]
  • [7] Regev A., Stark P., Blickstein D., Lahav M., Thrombotic complications in essential thrombocythemia with relatively low platelet counts, Am. J. Hematol., 1997, 56, 168–72 http://dx.doi.org/10.1002/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W[Crossref]
  • [8] Goldenberg N., Kahn S.R., Solymoss S., Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism, J. Clin. Oncol., 2003, 21, 4194–9 http://dx.doi.org/10.1200/JCO.2003.05.165[Crossref]
  • [9] Sack G.H.Jr., Levin J., Bell W.R., Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic, and therapeutic features, Medicine (Baltimore), 1977, 56, 1–37
  • [10] Donati M.B., Cancer and thrombosis: From phlegmasia alba dolens to transgenic mice, Thromb. Haemost., 1995, 74, 278–81
  • [11] Griesshammer M., Bangerter M., Sauer T., Wennauer R., Bergmann L., Heimpel H., Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count, J. Intern. Med., 1999, 245, 295–300 http://dx.doi.org/10.1046/j.1365-2796.1999.00452.x
  • [12] Buss D.H., Cashell A.W., O'Connor M.L., Richards F.2nd, Case L.D., Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases, Am. J. Med., 1994, 96, 247–53 http://dx.doi.org/10.1016/0002-9343(94)90150-3[Crossref]
  • [13] Arslan C., Coskun H.S., Thrombocytosis in solid tumors: review of the literature. Turk. J. Haematol., 2005, 22, 59–64
  • [14] Ikeda M., Furukawa H., Imamura H., Shimizu J., Ishida H., Masutani S., et al., Poor prognosis associated with thrombocytosis in patients with gastric cancer, Ann. Surg. Oncol., 2002, 9, 287–91 http://dx.doi.org/10.1007/BF02573067[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.